Design Therapeutics is developing small molecule therapeutic candidates through its GeneTAC™ platform to target the underlying causes of serious genetic disorders, such as Friedreich ataxia and Huntington’s disease. The company addresses the urgent medical need for functional cures in monogenic repeat expansion disorders, which currently lack effective treatment options.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LCFounders
Product
Problem
Many genetic disorders, such as Friedreich ataxia and Huntington’s disease, lack effective treatments that address the underlying cause of the disease. Current options often manage symptoms without providing a functional cure for monogenic repeat expansion disorders. This leaves a significant unmet medical need for therapies that can target and correct the genetic defects driving these conditions.
Solution
Design Therapeutics is developing small molecule therapeutic candidates designed to provide functional cures for serious genetic diseases. The company's GeneTAC™ (Gene Targeted Chimera) platform leverages an understanding of gene regulation and small molecule drug development to target the underlying causes of genetic disorders. This approach aims to correct the genetic defects responsible for the disease, rather than merely managing the symptoms. The company is focused on advancing a pipeline of novel candidates for monogenic repeat expansion disorders with urgent medical needs.
Target Audience
The primary target audience includes patients suffering from serious genetic disorders, particularly monogenic repeat expansion disorders like Friedreich ataxia, Fuchs endothelial corneal dystrophy, Huntington’s disease and myotonic dystrophy, as well as the healthcare providers who treat them.
Features
- GeneTAC™ platform designed to target and correct the underlying genetic causes of disease.
- Focus on small molecule therapeutics for improved drug delivery and efficacy.
- Pipeline of novel candidates targeting monogenic repeat expansion disorders.
- Development of functional cures rather than symptomatic treatments.